<DOC>
	<DOCNO>NCT02228473</DOCNO>
	<brief_summary>We want evaluate efficacy glycopyrrolate atropine prevention catheter-related bladder discomfort .</brief_summary>
	<brief_title>Effect Glycopyrrolate Atropine Catheter-Related Bladder Discomfort</brief_title>
	<detailed_description>The mechanism catheter-related bladder discomfort think related muscarinic receptor . The adjunct reversal agent glycopyrrolate atropine know block muscarinic receptor different way . We want evaluate efficacy glycopyrrolate atropine prevention catheter-related bladder discomfort .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Atropine</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Neuromuscular Blocking Agents</mesh_term>
	<criteria>Patients schedule transurethral bladder excision general anesthesia ASA IIII Foley catheter le 18 Fr . Patients obstruction urinary tract Patients neurogenic bladder Patients severe obesity Patients neurologic disorder Patients chronic pain Patients allergic history atropine glycopyrrolate</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>